Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Martin Maron and Barry Maron.
Martin Maron
Connection Strength
65.676
Barry Maron
  1. Maron BJ, Rowin EJ, Maron MS. Surgical Treatment of Hypertrophic Cardiomyopathy in Ukraine During War. JAMA Cardiol. 2025 May 07.
    View in: PubMed
    Score: 0.995
  2. Maron MS, Rowin EJ, Maron BJ. Letter by Maron et al Regarding Article, "Sudden Cardiac Death in National Collegiate Athletic Association Athletes". Circulation. 2024 Sep 17; 150(12):e255-e256.
    View in: PubMed
    Score: 0.952
  3. Maron MS, Rowin EJ, Maron BJ. The Paradigm of Sudden Death Prevention in Hypertrophic Cardiomyopathy. Am J Cardiol. 2024 02 01; 212S:S64-S76.
    View in: PubMed
    Score: 0.911
  4. Maron BJ, Rowin EJ, Maron MS. Advances in the Management of Hypertrophic Cardiomyopathy Leading to Low Disease-Related Mortality in 2023. Am J Cardiol. 2024 02 01; 212S:S77-S82.
    View in: PubMed
    Score: 0.911
  5. Maron BJ, Rowin EJ, Maron MS. Commotio cordis?once again: Unusual occurrence in a noncontact sport. HeartRhythm Case Rep. 2023 Dec; 9(12):855-857.
    View in: PubMed
    Score: 0.898
  6. Maron MS, Mitten M, Borchers J, Rowin EJ, Maron BJ. Medical and Legal Determinants of Sports Eligibility for Young Competitive Athletes With Cardiovascular Disease. J Am Coll Cardiol. 2023 08 29; 82(9):828-832.
    View in: PubMed
    Score: 0.881
  7. Maron MS, Rowin EJ, Bonaventura J, Maron BJ. Do Implantable Cardioverter-Defibrillators Really Belong on the Athlete Field? Am J Cardiol. 2023 08 01; 200:236-238.
    View in: PubMed
    Score: 0.875
  8. Maron MS, Rowin E, Spirito P, Maron BJ. Differing strategies for sudden death prevention in hypertrophic cardiomyopathy. Heart. 2023 03 27; 109(8):589-594.
    View in: PubMed
    Score: 0.860
  9. Maron BJ, Rowin EJ, Ambe SP, Maron MS. The Reply. Am J Med. 2023 03; 136(3):e50.
    View in: PubMed
    Score: 0.855
  10. Maron BJ, Dearani JA, Smedira NG, Schaff HV, Wang S, Rastegar H, Ralph-Edwards A, Ferrazzi P, Swistel D, Shemin RJ, Quintana E, Bannon PG, Shekar PS, Desai M, Roberts WC, Lever HM, Adler A, Rakowski H, Spirito P, Nishimura RA, Ommen SR, Sherrid MV, Rowin EJ, Maron MS. Ventricular Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy (Analysis Spanning 60 Years Of Practice): AJC Expert Panel. Am J Cardiol. 2022 10 01; 180:124-139.
    View in: PubMed
    Score: 0.823
  11. Maron MS, Lanuario EL, Rowin EJ, Maron BJ. Global Dissemination and Implementation of Contemporary Management Principles for Hypertrophic Cardiomyopathy and Role of the International HCM Summit. Am J Cardiol. 2022 06 01; 172:146-149.
    View in: PubMed
    Score: 0.812
  12. Maron BJ, Maron MS. Reflections on Six Decades of Hypertrophic Cardiomyopathy From Eugene Braunwald. Am J Cardiol. 2022 06 01; 172:150-153.
    View in: PubMed
    Score: 0.812
  13. Maron BJ, Maron MS. Jeff Zucker Says Hypertrophic Cardiomyopathy is a Curable Disease: A Patient's Perspective. Am J Cardiol. 2022 06 01; 172:154-156.
    View in: PubMed
    Score: 0.812
  14. Maron BJ, Rowin EJ, Ambe SP, Maron MS. Changing Demographics in Hypertrophic Cardiomyopathy and Implications for Management: Clinical Research. Am J Med. 2022 10; 135(10):1244-1246.
    View in: PubMed
    Score: 0.812
  15. Maron BJ, Rowin EJ, Madias C, Dolan N, Maron MS. Cats Have Nine Lives but This Hypertrophic Cardiomyopathy Patient Has Had Ten (So Far). Am J Cardiol. 2022 04 01; 168:163-165.
    View in: PubMed
    Score: 0.794
  16. Maron BJ, Rowin EJ, Maron MS. Hypertrophic Cardiomyopathy: New Concepts and Therapies. Annu Rev Med. 2022 01 27; 73:363-375.
    View in: PubMed
    Score: 0.793
  17. Maron MS, Rowin EJ, Maron BJ. Is surgical myectomy challenged by emergence of novel drug therapy with mavacamten? Asian Cardiovasc Thorac Ann. 2022 Jan; 30(1):11-18.
    View in: PubMed
    Score: 0.793
  18. Maron BJ, Rowin EJ, Maron MS. Is Regression of Left Ventricular Hypertrophy Really a Good Thing for Patients With Hypertrophic Cardiomyopathy?: The Emerging Mavacamten Story. Am J Cardiol. 2021 05 15; 147:145-146.
    View in: PubMed
    Score: 0.741
  19. Maron BJ, Rowin EJ, Maron MS. Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: Twenty years with the implantable cardioverter-defibrillator. Heart Rhythm. 2021 06; 18(6):1012-1023.
    View in: PubMed
    Score: 0.740
  20. Maron BJ, Rowin EJ, Maron MS. Erratum to "Hypertrophic Cardiomyopathy: Is a 'Cure' Coming ? Or Is It Already Here?": American Journal of Medicine, 133 (2020):8:886-888. Am J Med. 2021 Mar; 134(3):412.
    View in: PubMed
    Score: 0.737
  21. Maron BJ, Rowin EJ, Maron MS. After 60 Years Hypertrophic Cardiomyopathy is Finally Recognized as a Contemporary Treatable Disease With Low Mortality and Morbidity, But is This Paradigm Under-Recognized in the Literature? Am J Cardiol. 2021 03 01; 142:136-137.
    View in: PubMed
    Score: 0.733
  22. Maron MS, Rowin EJ, Maron BJ. Hypertrophic cardiomyopathy with left ventricular apical aneurysm: the newest high-risk phenotype. Eur Heart J Cardiovasc Imaging. 2020 12 01; 21(12):1351-1352.
    View in: PubMed
    Score: 0.732
  23. Maron BJ, Rowin EJ, Maron MS. Hypertrophic Cardiomyopathy: Is a 'Cure' Coming . . . Or Is It Already Here? Am J Med. 2020 08; 133(8):886-888.
    View in: PubMed
    Score: 0.715
  24. Maron MS, Steiger N, Burrows A, Madias C, Weinstock J, Link MS, Rowin EJ, Maron BJ. Evidence That Subcutaneous Implantable Cardioverter-Defibrillators Are Effective and Reliable in Hypertrophic Cardiomyopathy. JACC Clin Electrophysiol. 2020 08; 6(8):1019-1021.
    View in: PubMed
    Score: 0.715
  25. Maron MS, Brush J, Rowin EJ, Maron BJ. Back to the future: Predicting sudden death in hypertrophic cardiomyopathy relying on individual risk markers and physician judgment without mathematical scoring. Heart Rhythm. 2021 01; 18(1):148-150.
    View in: PubMed
    Score: 0.714
  26. Maron BJ, Maron MS. PRKAG2 Glycogen Storage Disease Cardiomyopathy: Out of the Darkness and Into the Light. J Am Coll Cardiol. 2020 07 14; 76(2):198-200.
    View in: PubMed
    Score: 0.713
  27. Maron BJ, Mackey-Bojack S, Facile E, Duncanson E, Rowin EJ, Maron MS. Hypertrophic Cardiomyopathy and Sudden Death Initially Identified at Autopsy. Am J Cardiol. 2020 07 15; 127:139-141.
    View in: PubMed
    Score: 0.702
  28. Maron BJ, Rowin EJ, Maron MS. Concerns About the HCM Risk-Kids Study. JAMA Cardiol. 2020 03 01; 5(3):362-363.
    View in: PubMed
    Score: 0.695
  29. Maron MS, Rowin EJ, Maron BJ. Editorial commentary: Hold your horses (and mice, rats, and cats): How relevant really are animal models of hypertrophic cardiomyopathy? Trends Cardiovasc Med. 2021 01; 31(1):32-33.
    View in: PubMed
    Score: 0.685
  30. Maron BJ, Harris KM, Maron MS. The Guidant Affair revisited?but this time with good news. Heart Rhythm. 2020 03; 17(3):512-513.
    View in: PubMed
    Score: 0.676
  31. Maron BJ, Rowin EJ, Maron MS. Paradigm of Sudden Death Prevention in Hypertrophic Cardiomyopathy. Circ Res. 2019 08 02; 125(4):370-378.
    View in: PubMed
    Score: 0.667
  32. Maron MS, Rowin EJ, Wessler BS, Mooney PJ, Fatima A, Patel P, Koethe BC, Romashko M, Link MS, Maron BJ. Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy. JAMA Cardiol. 2019 07 01; 4(7):644-657.
    View in: PubMed
    Score: 0.663
  33. Maron MS, Rowin EJ, Maron BJ. The ESC Risk Score Is Less Reliable than ACC/AHA Risk Factors in Hypertrophic Cardiomyopathy: When Sensitivity Trumps Specificity. Can J Cardiol. 2019 12; 35(12):1626-1628.
    View in: PubMed
    Score: 0.663
  34. Maron BJ, Rowin EJ, Maron MS. Letter by Maron et al Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)". Circulation. 2019 03 19; 139(12):1557-1558.
    View in: PubMed
    Score: 0.650
  35. Maron MS, Spirito P, Maron BJ. Case for Earlier Surgical Myectomy in Patients With Obstructive Hypertrophic Cardiomyopathy. Circulation. 2018 11 06; 138(19):2076-2078.
    View in: PubMed
    Score: 0.634
  36. Maron MS, Udelson JE, Rowin EJ, Maron BJ. Reply: Atrial Fibrillation in Hypertrophic Cardiomyopathy. JACC Heart Fail. 2018 09; 6(9):807-808.
    View in: PubMed
    Score: 0.626
  37. Maron BJ, Maron MS. Summary of Presentations and Discussions of Hypertrophic Cardiomyopathy at the 2018 Boston International Summit VI Including Consensus, Controversies, and Unmet Needs. Am J Cardiol. 2018 10 01; 122(7):1281-1286.
    View in: PubMed
    Score: 0.619
  38. Maron BJ, Rowin EJ, Maron MS. Global Burden of Hypertrophic?Cardiomyopathy. JACC Heart Fail. 2018 05; 6(5):376-378.
    View in: PubMed
    Score: 0.612
  39. Maron BJ, Rowin EJ, Udelson JE, Maron MS. Clinical Spectrum and Management?of?Heart Failure in?Hypertrophic?Cardiomyopathy. JACC Heart Fail. 2018 05; 6(5):353-363.
    View in: PubMed
    Score: 0.610
  40. Maron BJ, Estes NAM, Maron MS. Is It Fair to Screen Only Competitive Athletes for Sudden Death Risk, or Is It Time to Level the Playing Field? Am J Cardiol. 2018 04 15; 121(8):1008-1010.
    View in: PubMed
    Score: 0.602
  41. Maron MS, Xin W, Sims KB, Butler R, Haas TS, Rowin EJ, Desnick RJ, Maron BJ. Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy. Am J Med. 2018 02; 131(2):200.e1-200.e8.
    View in: PubMed
    Score: 0.587
  42. Maron MS, Rowin EJ, Maron BJ. How to Image Hypertrophic Cardiomyopathy. Circ Cardiovasc Imaging. 2017 07; 10(7).
    View in: PubMed
    Score: 0.578
  43. Maron BJ, Nishimura RA, Maron MS. Shared decision-making in HCM. Nat Rev Cardiol. 2017 03; 14(3):125-126.
    View in: PubMed
    Score: 0.561
  44. Maron BJ, Maron MS. A Discussion of Contemporary Nomenclature, Diagnosis, Imaging, and Management of Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2016 12 15; 118(12):1897-1907.
    View in: PubMed
    Score: 0.550
  45. Maron MS, Maron BJ. Reply: Nonobstructive Hypertrophic Cardiomyopathy: Low Mortality but Not Always Benign. J Am Coll Cardiol. 2016 08 30; 68(9):983.
    View in: PubMed
    Score: 0.545
  46. Maron BJ, Maron MS. LGE Means Better Selection of HCM?Patients for Primary Prevention Implantable Defibrillators. JACC Cardiovasc Imaging. 2016 12; 9(12):1403-1406.
    View in: PubMed
    Score: 0.541
  47. Maron BJ, Maron MS. The Remarkable 50 Years of Imaging in?HCM and How?it Has Changed Diagnosis?and Management: From M-Mode Echocardiography to CMR. JACC Cardiovasc Imaging. 2016 07; 9(7):858-872.
    View in: PubMed
    Score: 0.539
  48. Maron BJ, Rowin EJ, Casey SA, Maron MS. How Hypertrophic Cardiomyopathy Became a Contemporary Treatable Genetic Disease With Low Mortality: Shaped by 50 Years of Clinical Research and Practice. JAMA Cardiol. 2016 04 01; 1(1):98-105.
    View in: PubMed
    Score: 0.530
  49. Maron MS, Rowin EJ, Olivotto I, Casey SA, Arretini A, Tomberli B, Garberich RF, Link MS, Chan RHM, Lesser JR, Maron BJ. Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2016 Mar 29; 67(12):1399-1409.
    View in: PubMed
    Score: 0.529
  50. Maron MS, Maron BJ. Response to Letter Regarding Article, "Clinical Impact of Contemporary Cardiovascular Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy". Circulation. 2016 Mar 01; 133(9):e422.
    View in: PubMed
    Score: 0.527
  51. Maron BJ, Maron MS. Nonobstructive Hypertrophic Cardiomyopathy: Overlooked But Not Forgotten. Mayo Clin Proc. 2016 Mar; 91(3):277-8.
    View in: PubMed
    Score: 0.527
  52. Maron BJ, Maron MS. Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy. Heart Rhythm. 2016 05; 13(5):1155-1165.
    View in: PubMed
    Score: 0.521
  53. Maron BJ, Rowin EJ, Casey SA, Garberich RF, Maron MS. What Do Patients With Hypertrophic Cardiomyopathy Die from? Am J Cardiol. 2016 Feb 01; 117(3):434-5.
    View in: PubMed
    Score: 0.516
  54. Maron BJ, Udelson JE, Bonow RO, Nishimura RA, Ackerman MJ, Estes NAM, Cooper LT, Link MS, Maron MS. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2015 Dec 01; 66(21):2362-2371.
    View in: PubMed
    Score: 0.515
  55. Maron BJ, Levine BD, Washington RL, Baggish AL, Kovacs RJ, Maron MS. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 2: Preparticipation Screening for Cardiovascular Disease in Competitive Athletes: A Scientific Statement From the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2015 Dec 01; 66(21):2356-2361.
    View in: PubMed
    Score: 0.515
  56. Maron BJ, Rowin EJ, Casey SA, Lesser JR, Garberich RF, McGriff DM, Maron MS. Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. Circulation. 2016 Jan 05; 133(1):62-73.
    View in: PubMed
    Score: 0.514
  57. Maron MS, Maron BJ. Clinical Impact of Contemporary Cardiovascular Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy. Circulation. 2015 Jul 28; 132(4):292-8.
    View in: PubMed
    Score: 0.505
  58. Maron BJ, Casey SA, Chan RH, Garberich RF, Rowin EJ, Maron MS. Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy. Am J Cardiol. 2015 Sep 01; 116(5):757-64.
    View in: PubMed
    Score: 0.500
  59. Maron BJ, Rowin EJ, Kalra A, Lesser JR, Maron MS. Reply: To PMID 25759101. Am J Cardiol. 2015 Aug 01; 116(3):492-3.
    View in: PubMed
    Score: 0.499
  60. Maron BJ, Rowin EJ, Casey SA, Link MS, Lesser JR, Chan RH, Garberich RF, Udelson JE, Maron MS. Hypertrophic Cardiomyopathy in?Adulthood Associated With Low?Cardiovascular Mortality With Contemporary Management Strategies. J Am Coll Cardiol. 2015 May 12; 65(18):1915-28.
    View in: PubMed
    Score: 0.498
  61. Maron BJ, Maron MS. The 20 advances that have defined contemporary hypertrophic cardiomyopathy. Trends Cardiovasc Med. 2015 Jan; 25(1):54-64.
    View in: PubMed
    Score: 0.486
  62. Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Reply: Obstructive sleep apnea and hypertrophic cardiomyopathy: obiter dictum or more? J Am Coll Cardiol. 2014 Dec 16; 64(23):2562.
    View in: PubMed
    Score: 0.484
  63. Maron BJ, Maron MS. The 25-year genetic era in hypertrophic cardiomyopathy: revisited. Circ Cardiovasc Genet. 2014 Aug; 7(4):401-4.
    View in: PubMed
    Score: 0.472
  64. Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol. 2014 Jul 08; 64(1):83-99.
    View in: PubMed
    Score: 0.470
  65. Maron BJ, Rastegar H, Udelson JE, Dearani JA, Maron MS. Contemporary surgical management of hypertrophic cardiomyopathy, the need for more myectomy surgeons and disease-specific centers, and the Tufts initiative. Am J Cardiol. 2013 Nov 01; 112(9):1512-5.
    View in: PubMed
    Score: 0.443
  66. Maron BJ, Maron MS. Hypertrophic cardiomyopathy in childhood: the gradient is not the disease. Excessive use of experimental invasive interventions. J Am Coll Cardiol. 2013 Jan 15; 61(2):210-1.
    View in: PubMed
    Score: 0.424
  67. Maron BJ, Rowin EJ, Casey SA, Haas TS, Chan RH, Udelson JE, Garberich RF, Lesser JR, Appelbaum E, Manning WJ, Maron MS. Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of age. Circulation. 2013 Feb 05; 127(5):585-93.
    View in: PubMed
    Score: 0.423
  68. Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013 Jan 19; 381(9862):242-55.
    View in: PubMed
    Score: 0.411
  69. Maron MS, Rowin EJ, Lin D, Appelbaum E, Chan RH, Gibson CM, Lesser JR, Lindberg J, Haas TS, Udelson JE, Manning WJ, Maron BJ. Prevalence and clinical profile of myocardial crypts in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2012 Jul; 5(4):441-7.
    View in: PubMed
    Score: 0.404
  70. Maron MS, Olivotto I, Harrigan C, Appelbaum E, Gibson CM, Lesser JR, Haas TS, Udelson JE, Manning WJ, Maron BJ. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation. 2011 Jul 05; 124(1):40-7.
    View in: PubMed
    Score: 0.380
  71. Maron BJ, Lindberg J, Haas TS, Kitner C, Schum K, Lesser JR, Maron MS. "Speckled" ventricular septum in hypertrophic cardiomyopathy revisited after 30 years. Am J Cardiol. 2011 Jun 15; 107(12):1862-3.
    View in: PubMed
    Score: 0.375
  72. Maron MS, Lesser JR, Maron BJ. Management implications of massive left ventricular hypertrophy in hypertrophic cardiomyopathy significantly underestimated by echocardiography but identified by cardiovascular magnetic resonance. Am J Cardiol. 2010 Jun 15; 105(12):1842-3.
    View in: PubMed
    Score: 0.354
  73. Maron MS, Finley JJ, Bos JM, Hauser TH, Manning WJ, Haas TS, Lesser JR, Udelson JE, Ackerman MJ, Maron BJ. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation. 2008 Oct 07; 118(15):1541-9.
    View in: PubMed
    Score: 0.314
  74. Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C, Lesser JR, Udelson JE, Manning WJ, Maron BJ. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail. 2008 Sep; 1(3):184-91.
    View in: PubMed
    Score: 0.309
  75. Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, Nistri S, Cecchi F, Udelson JE, Maron BJ. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006 Nov 21; 114(21):2232-9.
    View in: PubMed
    Score: 0.276
  76. Maron BJ, Olivotto I, Maron MS. The dilemma of left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy: do patients with gradients really deserve prophylactic defibrillators? Eur Heart J. 2006 Aug; 27(16):1895-7.
    View in: PubMed
    Score: 0.270
  77. Maron MS, Zenovich AG, Casey SA, Link MS, Udelson JE, Aeppli DM, Maron BJ. Significance and relation between magnitude of left ventricular hypertrophy and heart failure symptoms in hypertrophic cardiomyopathy. Am J Cardiol. 2005 Jun 01; 95(11):1329-33.
    View in: PubMed
    Score: 0.250
  78. Sayed A, Maron BJ, Rowin EJ, Maron MS. Evidence of Declining Mortality Trends for Hypertrophic Cardiomyopathy in the United States and the Impact of the COVID-19 Pandemic. J Am Heart Assoc. 2025 Apr; 14(7):e037047.
    View in: PubMed
    Score: 0.247
  79. Maron BJ, Casey S, Sengupta JD, Sharkey SW, Maron MS, Rowin EJ. Experience With Extended Follow-Up of?Prophylactically Implanted Defibrillators?for High-Risk Patients With?Hypertrophic?Cardiomyopathy. JACC Adv. 2024 Nov; 3(11):101317.
    View in: PubMed
    Score: 0.239
  80. Rowin EJ, Das G, Madias C, Hsu M, Crosson L, Turakhia MP, Maron BJ, Maron MS. Extended Ambulatory ECG Monitoring Enhances Identification of Higher-Risk Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy. Heart Rhythm. 2024 Sep 20.
    View in: PubMed
    Score: 0.238
  81. Bonaventura J, Rowin EJ, Chan RH, Chin MT, Puchnerova V, Polakova E, Macek M, Votypka P, Batorsky R, Perera G, Koethe B, Veselka J, Maron BJ, Maron MS. Relationship Between Genotype Status and Clinical Outcome in Hypertrophic Cardiomyopathy. J Am Heart Assoc. 2024 May 21; 13(10):e033565.
    View in: PubMed
    Score: 0.233
  82. Abraham S, Rowin EJ, Saji AM, Silver JS, Shekar PS, Maron MS, Maron BJ. Significance and Frequency of Incidental Fortuitous Clinical Identifications of Hypertrophic Cardiomyopathy. JACC Adv. 2024 Jun; 3(6):100948.
    View in: PubMed
    Score: 0.232
  83. Maron BJ, Maron MS, Rowin EJ. Precision Medicine for All?: What About Hypertrophic Cardiomyopathy? JACC Adv. 2024 May; 3(5):100922.
    View in: PubMed
    Score: 0.231
  84. Rowin EJ, Wadid M, Maron MS, White M, Hook BG, Harnish P, Silver JS, Reynolds MR, Maron BJ. Assessing the impact of atrial fibrillation on symptoms and quality of life in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2024 Apr; 35(4):654-663.
    View in: PubMed
    Score: 0.228
  85. Rowin EJ, Link MS, Maron MS, Maron BJ. Evolving Contemporary Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation. 2023 11 28; 148(22):1797-1811.
    View in: PubMed
    Score: 0.225
  86. Maron BJ, Estes NAM, Rowin EJ, Maron MS, Reynolds MR. Development of the Implantable Cardioverter-Defibrillator: JACC Historical Breakthroughs in Perspective. J Am Coll Cardiol. 2023 07 25; 82(4):353-373.
    View in: PubMed
    Score: 0.220
  87. Bonaventura J, Maron BJ, Berul CI, Rowin EJ, Maron MS. Analysis of risk stratification and prevention of sudden death in pediatric patients with hypertrophic cardiomyopathy: Dilemmas and clarity. Heart Rhythm O2. 2023 Aug; 4(8):506-516.
    View in: PubMed
    Score: 0.218
  88. Bonaventura J, Rowin EJ, Maron MS, Maron BJ. Is Hypertrophic Cardiomyopathy Always a Familial and Inherited Disease? J Am Heart Assoc. 2023 06 20; 12(12):e028974.
    View in: PubMed
    Score: 0.218
  89. Maurizi N, Olivotto I, Maron MS, Bonacchi G, Antiochos P, Tomberli B, Fumagalli C, Poggesi C, Berteotti M, Girolami F, Cecchi F, Maron BJ. Lifetime Clinical Course of Hypertrophic?Cardiomyopathy: Outcome of the Historical Florence Cohort Over 5 Decades. JACC Adv. 2023 Jun; 2(4):100337.
    View in: PubMed
    Score: 0.217
  90. Massera D, Sherrid MV, Maron MS, Rowin EJ, Maron BJ. How common is hypertrophic cardiomyopathy? really?: Disease prevalence revisited 27?years after CARDIA. Int J Cardiol. 2023 07 01; 382:64-67.
    View in: PubMed
    Score: 0.215
  91. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003 Jan 23; 348(4):295-303.
    View in: PubMed
    Score: 0.212
  92. Bonaventura J, Rowin EJ, Maron MS, Maron BJ. Risks of the Athletic Field Revisited: Report of Unusual Occurrences of Cardiac Arrest and Sudden Death in Professional Soccer Players. Am J Med. 2023 03; 136(3):315-321.
    View in: PubMed
    Score: 0.211
  93. Rowin EJ, Ruberg FL, Das G, Higgins D, Lipe WC, Bokhari N, Dehn M, Maron BJ, Maron MS. Identification of Transthyretin Cardiac Amyloidosis Among Patients Previously Diagnosed With Hypertrophic Cardiomyopathy. Circ Cardiovasc Imaging. 2022 12; 15(12):e014938.
    View in: PubMed
    Score: 0.210
  94. Maron BA, Kleiner DE, Arons E, Wertheim BM, Sharma NS, Haley KJ, Samokhin AO, Rowin EJ, Maron MS, Rosing DR, Maron BJ. Evidence of Advanced Pulmonary Vascular Remodeling in Obstructive Hypertrophic Cardiomyopathy With Pulmonary Hypertension. Chest. 2023 03; 163(3):678-686.
    View in: PubMed
    Score: 0.208
  95. Abdelfattah OM, Martinez M, Sayed A, ElRefaei M, Abushouk AI, Hassan A, Masri A, Winters SL, Kapadia SR, Maron BJ, Rowin E, Maron MS. Temporal and Global Trends of the Incidence of Sudden Cardiac Death in Hypertrophic Cardiomyopathy. JACC Clin Electrophysiol. 2022 11; 8(11):1417-1427.
    View in: PubMed
    Score: 0.208
  96. Maron BJ, Maron MS, Sherrid MV, Ommen SR, Rowin EJ. Personalized Treatment Strategies Effective in Hypertrophic Cardiomyopathy Do Not Rely on Genomics in 2022: A Different Tale of Precision Medicine. Am J Cardiol. 2022 11 15; 183:150-152.
    View in: PubMed
    Score: 0.207
  97. Maron BA, Wang RS, Carnethon MR, Rowin EJ, Loscalzo J, Maron BJ, Maron MS. What Causes Hypertrophic Cardiomyopathy? Am J Cardiol. 2022 09 15; 179:74-82.
    View in: PubMed
    Score: 0.205
  98. Rowin EJ, Cooper C, Carrick RT, Tsoi M, Maron BJ, Maron MS. Ventricular Septal Myectomy Decreases Long-Term Risk for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2022 09 15; 179:70-73.
    View in: PubMed
    Score: 0.205
  99. Cui H, Schaff HV, Wang S, Lahr BD, Rowin EJ, Rastegar H, Hu S, Eleid MF, Dearani JA, Kimmelstiel C, Maron BJ, Nishimura RA, Ommen SR, Maron MS. Survival Following Alcohol Septal Ablation or Septal Myectomy for Patients?With Obstructive Hypertrophic?Cardiomyopathy. J Am Coll Cardiol. 2022 05 03; 79(17):1647-1655.
    View in: PubMed
    Score: 0.202
  100. Maron BJ, Maron MS, Sherrid MV, Rowin EJ. Future Role of New Negative Inotropic Agents in the Era of Established Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy. J Am Heart Assoc. 2022 05 03; 11(9):e024566.
    View in: PubMed
    Score: 0.202
  101. Maron MS, Rosing DR, Braunwald E, Rastegar H, Koethe B, Roberts WC, Maron BJ, Rowin EJ. Sixty-Year Evolution of Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy with Insights From the Historic NIH Surgical Experience to Present. Am J Cardiol. 2022 06 01; 172:107-108.
    View in: PubMed
    Score: 0.201
  102. Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, Rowin EJ, Maron MS, Sherrid MV. Diagnosis and Evaluation of Hypertrophic?Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022 02 01; 79(4):372-389.
    View in: PubMed
    Score: 0.198
  103. Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, Dearani JA, Rowin EJ, Maron MS, Sherrid MV. Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022 02 01; 79(4):390-414.
    View in: PubMed
    Score: 0.198
  104. Rowin EJ, Maron MS, Adler A, Albano AJ, Varnava AM, Spears D, Marsy D, Heitner SB, Cohen E, Leong KMW, Winters SL, Martinez MW, Koethe BC, Rakowski H, Maron BJ. Importance of newer cardiac magnetic resonance-based risk markers for sudden death prevention in hypertrophic cardiomyopathy: An international multicenter study. Heart Rhythm. 2022 05; 19(5):782-789.
    View in: PubMed
    Score: 0.197
  105. Maron MS, Rastegar H, Dolan N, Carpino P, Koethe B, Maron BJ, Rowin EJ. Outcomes Over Follow-up =10 Years After Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy. Am J Cardiol. 2022 01 15; 163:91-97.
    View in: PubMed
    Score: 0.196
  106. Maron BJ, Maron MS, Maurer MS, Rowin EJ, Maron BA, Gali? N. Cardiovascular Diseases That Have Emerged From the Darkness. J Am Heart Assoc. 2021 10 19; 10(20):e021095.
    View in: PubMed
    Score: 0.194
  107. Rowin EJ, Maron BJ, Wells S, Burrows A, Firely C, Koethe B, Patel AR, Maron MS. Usefulness of Global Longitudinal Strain to Predict Heart Failure Progression in Patients With Nonobstructive Hypertrophic Cardiomyopathy. Am J Cardiol. 2021 07 15; 151:86-92.
    View in: PubMed
    Score: 0.191
  108. Shirani J, Aurshiya R, Elshaikh A, Olenchock SA, Rowin EJ, Maron MS, Maron BJ. Low Risk of Hypertrophic Cardiomyopathy With Contemporary Management Strategies Implemented in Non-Referral Regional Community-Based Practices. Am J Cardiol. 2021 03 01; 142:130-135.
    View in: PubMed
    Score: 0.183
  109. Rowin EJ, Burrows A, Madias C, Estes NAM, Link MS, Maron MS, Maron BJ. Long-Term Outcome in High-Risk Patients With Hypertrophic Cardiomyopathy After Primary Prevention Defibrillator Implants. Circ Arrhythm Electrophysiol. 2020 10; 13(10):e008123.
    View in: PubMed
    Score: 0.180
  110. Rowin EJ, Maron BJ, Maron MS. Reply: The LVAD in the Management of Advanced Heart?Failure Due to Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2020 10 20; 76(16):1913.
    View in: PubMed
    Score: 0.179
  111. Rowin EJ, Maron BJ, Carrick RT, Patel PP, Koethe B, Wells S, Maron MS. Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction. J Am Coll Cardiol. 2020 06 23; 75(24):3033-3043.
    View in: PubMed
    Score: 0.178
  112. Rowin EJ, Sridharan A, Madias C, Firely C, Koethe B, Link MS, Maron MS, Maron BJ. Prediction and Prevention of Sudden Death in Young Patients (<20 years) With Hypertrophic Cardiomyopathy. Am J Cardiol. 2020 08 01; 128:75-83.
    View in: PubMed
    Score: 0.176
  113. Maron BJ, Rowin EJ, Arkun K, Rastegar H, Larson AM, Maron MS, Chin MT. Adult Monozygotic Twins With Hypertrophic Cardiomyopathy and Identical Disease Expression and Clinical Course. Am J Cardiol. 2020 07 15; 127:135-138.
    View in: PubMed
    Score: 0.175
  114. Rowin EJ, Maron MS, Bhatt V, Gillam L, Maron BJ. Hypertrophic Cardiomyopathy in "Real-World" Community Cardiology Practice. Am J Cardiol. 2020 05 01; 125(9):1398-1403.
    View in: PubMed
    Score: 0.173
  115. Rowin EJ, Maron BJ, Maron MS. The Hypertrophic Cardiomyopathy Phenotype Viewed Through the Prism?of?Multimodality Imaging: Clinical and Etiologic Implications. JACC Cardiovasc Imaging. 2020 09; 13(9):2002-2016.
    View in: PubMed
    Score: 0.171
  116. Sharkey SW, Kalra A, Henry TD, Smith TD, Pink VR, Lesser JR, Garberich RF, Maron MS, Maron BJ. Coexistence of acute takotsubo syndrome and acute coronary syndrome. Catheter Cardiovasc Interv. 2020 10 01; 96(4):825-829.
    View in: PubMed
    Score: 0.170
  117. Rowin EJ, Maron MS, Wells S, Patel PP, Koethe BC, Maron BJ. Impact of Sex on Clinical Course and Survival in the Contemporary Treatment Era for Hypertrophic Cardiomyopathy. J Am Heart Assoc. 2019 11 05; 8(21):e012041.
    View in: PubMed
    Score: 0.170
  118. Boll G, Rowin EJ, Maron BJ, Wang W, Rastegar H, Maron MS. Efficacy of Combined Cox-Maze IV and Ventricular Septal Myectomy for Treatment of Atrial Fibrillation in Patients With Obstructive Hypertrophic Cardiomyopathy. Am J Cardiol. 2020 01 01; 125(1):120-126.
    View in: PubMed
    Score: 0.169
  119. Rowin EJ, Romashko M, Testani JM, Koethe BC, Saxena D, Udelson JE, Maron BJ, Maron MS. Chronic Heart Failure Is Infrequently Associated With Renal Dysfunction in Hypertrophic Cardiomyopathy. J Card Fail. 2019 08; 25(8):690-692.
    View in: PubMed
    Score: 0.165
  120. Maron BJ, Maron MS, Maron BA, Loscalzo J. Moving Beyond the Sarcomere to Explain?Heterogeneity in Hypertrophic?Cardiomyopathy: JACC Review Topic of the Week. J Am Coll Cardiol. 2019 04 23; 73(15):1978-1986.
    View in: PubMed
    Score: 0.164
  121. Rowin EJ, Maron BJ, Romashko M, Wang W, Rastegar H, Link MS, Maron MS. Impact of Effective Management Strategies on Patients With the Most Extreme Phenotypic Expression of Hypertrophic Cardiomyopathy. Am J Cardiol. 2019 07 01; 124(1):113-121.
    View in: PubMed
    Score: 0.163
  122. Maurizi N, Michels M, Rowin EJ, Semsarian C, Girolami F, Tomberli B, Cecchi F, Maron MS, Olivotto I, Maron BJ. Clinical Course and Significance of Hypertrophic Cardiomyopathy Without Left Ventricular Hypertrophy. Circulation. 2019 02 05; 139(6):830-833.
    View in: PubMed
    Score: 0.161
  123. Rowin EJ, Mohanty S, Madias C, Maron BJ, Maron MS. Benefit of Cardiac Resynchronization Therapy in End-Stage Nonobstructive Hypertrophic Cardiomyopathy. JACC Clin Electrophysiol. 2019 01; 5(1):131-133.
    View in: PubMed
    Score: 0.160
  124. Rowin EJ, Maron BJ, Chokshi A, Kannappan M, Arkun K, Wang W, Rastegar H, Maron MS. Clinical Spectrum and Management Implications of Left Ventricular Outflow Obstruction With Mild Ventricular Septal Thickness in Hypertrophic Cardiomyopathy. Am J Cardiol. 2018 10 15; 122(8):1409-1420.
    View in: PubMed
    Score: 0.155
  125. Rowin EJ, Maron BJ, Chokshi A, Maron MS. Left?ventricular apical aneurysm in hypertrophic cardiomyopathy as a risk factor for sudden death at any age. Pacing Clin Electrophysiol. 2018 Jun 12.
    View in: PubMed
    Score: 0.154
  126. Rowin EJ, Maron MS, Maron BJ. Response by Rowin et al to Letter Regarding Article, "Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy". Circulation. 2018 06 05; 137(23):2541-2542.
    View in: PubMed
    Score: 0.154
  127. Wells S, Rowin EJ, Bhatt V, Maron MS, Maron BJ. Association Between Race and Clinical Profile of Patients Referred for Hypertrophic Cardiomyopathy. Circulation. 2018 05 01; 137(18):1973-1975.
    View in: PubMed
    Score: 0.153
  128. Maron BJ, Casey SA, Olivotto I, Sherrid MV, Semsarian C, Autore C, Ahmed A, Boriani G, Francia P, Winters SL, Giudici M, Koulova A, Garberich R, Rowin EJ, Sears SF, Maron MS, Spirito P. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators. Circ Arrhythm Electrophysiol. 2018 04; 11(4):e005820.
    View in: PubMed
    Score: 0.152
  129. Maron MS, Chan RH, Kapur NK, Jaffe IZ, McGraw AP, Kerur R, Maron BJ, Udelson JE. Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy. Am J Med. 2018 07; 131(7):837-841.
    View in: PubMed
    Score: 0.152
  130. Wells S, Rowin EJ, Boll G, Rastegar H, Wang W, Maron MS, Maron BJ. Clinical Profile of Nonresponders to Surgical Myectomy with Obstructive Hypertrophic Cardiomyopathy. Am J Med. 2018 06; 131(6):e235-e239.
    View in: PubMed
    Score: 0.150
  131. Rowin EJ, Maron BJ, Olivotto I, Maron MS. Role of Exercise Testing in Hypertrophic?Cardiomyopathy. JACC Cardiovasc Imaging. 2017 11; 10(11):1374-1386.
    View in: PubMed
    Score: 0.148
  132. Rowin EJ, Maron MS, Chan RH, Hausvater A, Wang W, Rastegar H, Maron BJ. Interaction of Adverse Disease Related Pathways in Hypertrophic Cardiomyopathy. Am J Cardiol. 2017 Dec 15; 120(12):2256-2264.
    View in: PubMed
    Score: 0.147
  133. Rowin EJ, Hausvater A, Link MS, Abt P, Gionfriddo W, Wang W, Rastegar H, Estes NAM, Maron MS, Maron BJ. Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation. 2017 Dec 19; 136(25):2420-2436.
    View in: PubMed
    Score: 0.147
  134. Rowin EJ, Maron BJ, Arkun K, Maron MS. Anatomic validation of late gadolinium enhancement as evidence of myocardial scarring in LAMP2 cardiomyopathy. Eur Heart J. 2017 08 14; 38(31):2444.
    View in: PubMed
    Score: 0.146
  135. Maron BJ, Rowin EJ, Maron MS, Braunwald E. Achieving Extended Longevity and Quality of Life for Senior Patients With Hypertrophic Cardiomyopathy: What Is Possible. Am J Med. 2017 Nov; 130(11):1236-1237.
    View in: PubMed
    Score: 0.145
  136. Rowin EJ, Maron BJ, Maron MS. Reply: Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm. J Am Coll Cardiol. 2017 07 18; 70(3):407.
    View in: PubMed
    Score: 0.145
  137. Maron BJ, Maron MS, Rowin EJ. Perspectives on the Overall Risks of Living With Hypertrophic Cardiomyopathy. Circulation. 2017 06 13; 135(24):2317-2319.
    View in: PubMed
    Score: 0.144
  138. Link MS, Bockstall K, Weinstock J, Alsheikh-Ali AA, Semsarian C, Estes NAM, Spirito P, Haas TS, Rowin EJ, Maron MS, Maron BJ. Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy and Defibrillators: Triggers, Treatment, and Implications. J Cardiovasc Electrophysiol. 2017 May; 28(5):531-537.
    View in: PubMed
    Score: 0.142
  139. Rowin EJ, Orfanos A, Estes NAM, Wang W, Link MS, Maron MS, Maron BJ. Occurrence and Natural History of Clinically Silent Episodes of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Am J Cardiol. 2017 06 01; 119(11):1862-1865.
    View in: PubMed
    Score: 0.142
  140. Rowin EJ, Maron BJ, Haas TS, Garberich RF, Wang W, Link MS, Maron MS. Hypertrophic Cardiomyopathy With Left?Ventricular Apical Aneurysm: Implications for Risk Stratification and Management. J Am Coll Cardiol. 2017 02 21; 69(7):761-773.
    View in: PubMed
    Score: 0.141
  141. Maron BJ, Dearani JA, Maron MS, Ommen SR, Rastegar H, Nishimura RA, Swistel DG, Sherrid MV, Ralph-Edwards A, Rakowski H, Smedira NG, Rowin EJ, Desai MY, Lever HM, Spirito P, Ferrazzi P, Schaff HV. Why we need more septal myectomy surgeons: An emerging recognition. J Thorac Cardiovasc Surg. 2017 11; 154(5):1681-1685.
    View in: PubMed
    Score: 0.140
  142. Maron BJ, Rowin EJ, Maron MS, Braunwald E. Nonobstructive Hypertrophic Cardiomyopathy Out of the Shadows: Known from the Beginning but Largely Ignored ? Until Now. Am J Med. 2017 02; 130(2):119-123.
    View in: PubMed
    Score: 0.137
  143. Kalra A, Harris KM, Maron BA, Maron MS, Garberich RF, Haas TS, Lesser JR, Maron BJ. Relation of Doppler Tissue Imaging Parameters With Heart Failure Progression in Hypertrophic Cardiomyopathy. Am J Cardiol. 2016 06 01; 117(11):1808-14.
    View in: PubMed
    Score: 0.132
  144. Maron BJ, Udelson JE, Bonow RO, Nishimura RA, Ackerman MJ, Estes NA, Cooper LT, Link MS, Maron MS. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Association and American College of Cardiology. Circulation. 2015 Dec 01; 132(22):e273-80.
    View in: PubMed
    Score: 0.129
  145. Semsarian C, Ingles J, Maron MS, Maron BJ. Reply: What Is the True Prevalence of Hypertrophic Cardiomyopathy? J Am Coll Cardiol. 2015 Oct 20; 66(16):1846-1847.
    View in: PubMed
    Score: 0.128
  146. Maron BJ, Dearani JA, Ommen SR, Maron MS, Schaff HV, Nishimura RA, Ralph-Edwards A, Rakowski H, Sherrid MV, Swistel DG, Balaram S, Rastegar H, Rowin EJ, Smedira NG, Lytle BW, Desai MY, Lever HM. Low Operative Mortality Achieved With Surgical Septal Myectomy: Role of Dedicated Hypertrophic Cardiomyopathy Centers in the Management of Dynamic Subaortic Obstruction. J Am Coll Cardiol. 2015 Sep 15; 66(11):1307-1308.
    View in: PubMed
    Score: 0.128
  147. Sharkey SW, Pink VR, Lesser JR, Garberich RF, Maron MS, Maron BJ. Clinical Profile of Patients With High-Risk Tako-Tsubo Cardiomyopathy. Am J Cardiol. 2015 Sep 01; 116(5):765-72.
    View in: PubMed
    Score: 0.125
  148. Chan RH, Maron BJ, Olivotto I, Assenza GE, Haas TS, Lesser JR, Gruner C, Crean AM, Rakowski H, Rowin E, Udelson J, Lombardi M, Tomberli B, Spirito P, Formisano F, Marra MP, Biagini E, Autore C, Manning WJ, Appelbaum E, Roberts WC, Basso C, Maron MS. Significance of Late Gadolinium Enhancement at Right Ventricular Attachment to Ventricular Septum in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2015 Aug 01; 116(3):436-41.
    View in: PubMed
    Score: 0.124
  149. Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015 Mar 31; 65(12):1249-1254.
    View in: PubMed
    Score: 0.124
  150. Kalra A, Maron MS, Rowin EJ, Colgan TK, Lesser JR, Maron BJ. Coronary embolization in hypertrophic cardiomyopathy with left ventricular apical aneurysm. Am J Cardiol. 2015 May 01; 115(9):1318-9.
    View in: PubMed
    Score: 0.122
  151. Maron BJ, Weiner HL, Maron MS, Roberts WC. Surviving malignant hypertrophic cardiomyopathy with all major complications in a single patient. Am J Cardiol. 2015 Feb 01; 115(3):402-4.
    View in: PubMed
    Score: 0.120
  152. Rowin EJ, Maron BJ, Kiernan MS, Casey SA, Feldman DS, Hryniewicz KM, Chan RH, Harris KM, Udelson JE, DeNofrio D, Roberts WC, Maron MS. Advanced heart failure with preserved systolic function in nonobstructive hypertrophic cardiomyopathy: under-recognized subset of candidates for heart transplant. Circ Heart Fail. 2014 Nov; 7(6):967-75.
    View in: PubMed
    Score: 0.119
  153. Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, Lesser JR, Gruner C, Crean AM, Rakowski H, Udelson JE, Rowin E, Lombardi M, Cecchi F, Tomberli B, Spirito P, Formisano F, Biagini E, Rapezzi C, De Cecco CN, Autore C, Cook EF, Hong SN, Gibson CM, Manning WJ, Appelbaum E, Maron MS. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014 Aug 05; 130(6):484-95.
    View in: PubMed
    Score: 0.118
  154. Gruner C, Chan RH, Crean A, Rakowski H, Rowin EJ, Care M, Deva D, Williams L, Appelbaum E, Gibson CM, Lesser JR, Haas TS, Udelson JE, Manning WJ, Siminovitch K, Ralph-Edwards AC, Rastegar H, Maron BJ, Maron MS. Significance of left ventricular apical-basal muscle bundle identified by cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Eur Heart J. 2014 Oct 14; 35(39):2706-13.
    View in: PubMed
    Score: 0.116
  155. Maron BJ, Haas TS, Maron MS, Lesser JR, Browning JA, Chan RH, Olivotto I, Garberich RF, Schwartz RS. Left atrial remodeling in hypertrophic cardiomyopathy and susceptibility markers for atrial fibrillation identified by cardiovascular magnetic resonance. Am J Cardiol. 2014 Apr 15; 113(8):1394-400.
    View in: PubMed
    Score: 0.114
  156. Olivotto I, Maron BJ, Tomberli B, Appelbaum E, Salton C, Haas TS, Gibson CM, Nistri S, Servettini E, Chan RH, Udelson JE, Lesser JR, Cecchi F, Manning WJ, Maron MS. Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013 Jul 30; 62(5):449-57.
    View in: PubMed
    Score: 0.108
  157. Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes NA, Shannon KM, Ashley EA, Day SM, Pacileo G, Formisano F, Devoto E, Anastasakis A, Bos JM, Woo A, Autore C, Pass RH, Boriani G, Garberich RF, Almquist AK, Russell MW, Boni L, Berger S, Maron MS, Link MS. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013 Apr 09; 61(14):1527-35.
    View in: PubMed
    Score: 0.108
  158. Rowin EJ, Maron BJ, Lesser JR, Rastegar H, Maron MS. Papillary muscle insertion directly into the anterior mitral leaflet in hypertrophic cardiomyopathy, its identification and cause of outflow obstruction by cardiac magnetic resonance imaging, and its surgical management. Am J Cardiol. 2013 Jun 01; 111(11):1677-9.
    View in: PubMed
    Score: 0.107
  159. Rowin EJ, Maron BJ, Maron MS. Reply: To PMID 23245842. Am J Cardiol. 2013 Jan 01; 111(1):150-1.
    View in: PubMed
    Score: 0.106
  160. Alsheikh-Ali AA, Link MS, Semsarian C, Shen WK, Estes NA, Maron MS, Haas TS, Formisano F, Boriani G, Spirito P, Maron BJ. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients. Heart Rhythm. 2013 Feb; 10(2):214-8.
    View in: PubMed
    Score: 0.104
  161. Rowin EJ, Maron BJ, Appelbaum E, Link MS, Gibson CM, Lesser JR, Haas TS, Udelson JE, Manning WJ, Maron MS. Significance of false negative electrocardiograms in preparticipation screening of athletes for hypertrophic cardiomyopathy. Am J Cardiol. 2012 Oct 01; 110(7):1027-32.
    View in: PubMed
    Score: 0.102
  162. Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol. 2012 Aug 21; 60(8):705-15.
    View in: PubMed
    Score: 0.102
  163. Sharkey SW, Lesser JR, Garberich RF, Pink VR, Maron MS, Maron BJ. Comparison of circadian rhythm patterns in Tako-tsubo cardiomyopathy versus ST-segment elevation myocardial infarction. Am J Cardiol. 2012 Sep 15; 110(6):795-9.
    View in: PubMed
    Score: 0.101
  164. Nistri S, Olivotto I, Maron MS, Ferrantini C, Coppini R, Grifoni C, Baldini K, Sgalambro A, Cecchi F, Maron BJ. ? Blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2012 Sep 01; 110(5):715-9.
    View in: PubMed
    Score: 0.101
  165. Pelliccia A, Maron MS, Maron BJ. Assessment of left ventricular hypertrophy in a trained athlete: differential diagnosis of physiologic athlete's heart from pathologic hypertrophy. Prog Cardiovasc Dis. 2012 Mar-Apr; 54(5):387-96.
    View in: PubMed
    Score: 0.100
  166. Rowin EJ, Maron MS, Lesser JR, Maron BJ. CMR with late gadolinium enhancement in genotype positive-phenotype negative hypertrophic cardiomyopathy. JACC Cardiovasc Imaging. 2012 Jan; 5(1):119-22.
    View in: PubMed
    Score: 0.099
  167. Appelbaum E, Maron BJ, Adabag S, Hauser TH, Lesser JR, Haas TS, Riley AB, Harrigan CJ, Delling FN, Udelson JE, Gibson CM, Manning WJ, Maron MS. Intermediate-signal-intensity late gadolinium enhancement predicts ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2012 Jan; 5(1):78-85.
    View in: PubMed
    Score: 0.098
  168. Maron BJ, Maron MS, Semsarian C. Double or compound sarcomere mutations in hypertrophic cardiomyopathy: a potential link to sudden death in the absence of conventional risk factors. Heart Rhythm. 2012 Jan; 9(1):57-63.
    View in: PubMed
    Score: 0.096
  169. Maron BJ, Maron MS, Maron BA, Haas TS, Altman RK, Smalley SJ, Doerer JJ, Link MS, Mooney MR. Successful therapeutic hypothermia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2011 Jun 14; 57(24):2454-6.
    View in: PubMed
    Score: 0.095
  170. Sharkey SW, Lesser JR, Maron MS, Maron BJ. Why not just call it tako-tsubo cardiomyopathy: a discussion of nomenclature. J Am Coll Cardiol. 2011 Mar 29; 57(13):1496-7.
    View in: PubMed
    Score: 0.094
  171. Nistri S, Olivotto I, Maron MS, Grifoni C, Baldini K, Baldi M, Sgalambro A, Cecchi F, Maron BJ. Timing and significance of exercise-induced left ventricular outflow tract pressure gradients in hypertrophic cardiomyopathy. Am J Cardiol. 2010 Nov 01; 106(9):1301-6.
    View in: PubMed
    Score: 0.090
  172. Olivotto I, Maron BJ, Appelbaum E, Harrigan CJ, Salton C, Gibson CM, Udelson JE, O'Donnell C, Lesser JR, Manning WJ, Maron MS. Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol. 2010 Jul 15; 106(2):261-7.
    View in: PubMed
    Score: 0.089
  173. Sharkey SW, Windenburg DC, Lesser JR, Maron MS, Hauser RG, Lesser JN, Haas TS, Hodges JS, Maron BJ. Natural history and expansive clinical profile of stress (tako-tsubo) cardiomyopathy. J Am Coll Cardiol. 2010 Jan 26; 55(4):333-41.
    View in: PubMed
    Score: 0.086
  174. Cecchi F, Olivotto I, Baldi M, Maron MS, Maron BJ. [Myocardial hypoperfusion due to microvascular dysfunction in hypertrophic cardiomyopathy: role of positron emission tomography]. Zhonghua Xin Xue Guan Bing Za Zhi. 2009 Dec; 37(12):1069-73.
    View in: PubMed
    Score: 0.085
  175. Maron MS, Olivotto I, Maron BJ, Prasad SK, Cecchi F, Udelson JE, Camici PG. The case for myocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009 Aug 25; 54(9):866-75.
    View in: PubMed
    Score: 0.084
  176. Maron BJ, Maron MS, Wigle ED, Braunwald E. The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy: from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009 Jul 14; 54(3):191-200.
    View in: PubMed
    Score: 0.083
  177. Maron MS, Maron BJ, Harrigan C, Buros J, Gibson CM, Olivotto I, Biller L, Lesser JR, Udelson JE, Manning WJ, Appelbaum E. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol. 2009 Jul 14; 54(3):220-8.
    View in: PubMed
    Score: 0.083
  178. Spirito P, Autore C, Rapezzi C, Bernab? P, Badagliacca R, Maron MS, Bongioanni S, Coccolo F, Estes NA, Barill? CS, Biagini E, Quarta G, Conte MR, Bruzzi P, Maron BJ. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation. 2009 Apr 07; 119(13):1703-10.
    View in: PubMed
    Score: 0.081
  179. Maron BJ, Seidman CE, Ackerman MJ, Towbin JA, Maron MS, Ommen SR, Nishimura RA, Gersh BJ. How should hypertrophic cardiomyopathy be classified?: What's in a name? Dilemmas in nomenclature characterizing hypertrophic cardiomyopathy and left ventricular hypertrophy. Circ Cardiovasc Genet. 2009 Feb; 2(1):81-5; discussion 86.
    View in: PubMed
    Score: 0.081
  180. Olivotto I, Maron MS, Autore C, Lesser JR, Rega L, Casolo G, De Santis M, Quarta G, Nistri S, Cecchi F, Salton CJ, Udelson JE, Manning WJ, Maron BJ. Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008 Aug 12; 52(7):559-66.
    View in: PubMed
    Score: 0.078
  181. Sharkey SW, Lesser JR, Menon M, Parpart M, Maron MS, Maron BJ. Spectrum and significance of electrocardiographic patterns, troponin levels, and thrombolysis in myocardial infarction frame count in patients with stress (tako-tsubo) cardiomyopathy and comparison to those in patients with ST-elevation anterior wall myocardial infarction. Am J Cardiol. 2008 Jun 15; 101(12):1723-8.
    View in: PubMed
    Score: 0.076
  182. Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, Lesser JR, Hanna CA, Udelson JE, Manning WJ, Maron MS. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol. 2008 Apr 08; 51(14):1369-74.
    View in: PubMed
    Score: 0.076
  183. Harrigan CJ, Appelbaum E, Maron BJ, Buros JL, Gibson CM, Lesser JR, Udelson JE, Manning WJ, Maron MS. Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol. 2008 Mar 01; 101(5):668-73.
    View in: PubMed
    Score: 0.075
  184. Maron BJ, Maron MS, Lesser JR, Hauser RG, Haas TS, Harrigan CJ, Appelbaum E, Main ML, Roberts WC. Sudden cardiac arrest in hypertrophic cardiomyopathy in the absence of conventional criteria for high risk status. Am J Cardiol. 2008 Feb 15; 101(4):544-7.
    View in: PubMed
    Score: 0.075
  185. Olivotto I, Ommen SR, Maron MS, Cecchi F, Maron BJ. Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Will there ever be a randomized trial? J Am Coll Cardiol. 2007 Aug 28; 50(9):831-4.
    View in: PubMed
    Score: 0.073
  186. Maron BJ, Thompson PD, Ackerman MJ, Balady G, Berger S, Cohen D, Dimeff R, Douglas PS, Glover DW, Hutter AM, Krauss MD, Maron MS, Mitten MJ, Roberts WO, Puffer JC. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation. 2007 Mar 27; 115(12):1643-455.
    View in: PubMed
    Score: 0.071
  187. Sharkey SW, Lesser JR, Maron MS, Maron BJ. Stress cardiomyopathy. J Am Coll Cardiol. 2007 Feb 27; 49(8):921; author reply 921-2.
    View in: PubMed
    Score: 0.070
  188. Harris KM, Spirito P, Maron MS, Zenovich AG, Formisano F, Lesser JR, Mackey-Bojack S, Manning WJ, Udelson JE, Maron BJ. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006 Jul 18; 114(3):216-25.
    View in: PubMed
    Score: 0.067
  189. Olivotto I, Maron MS, Adabag AS, Casey SA, Vargiu D, Link MS, Udelson JE, Cecchi F, Maron BJ. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005 Aug 02; 46(3):480-7.
    View in: PubMed
    Score: 0.063
  190. Fath AR, Aglan A, Maron MS, Phillips JS, Maron BJ, Rowin EJ. Cardiovascular outcomes of glucagon-like peptide-1 agonist in patients with obesity and hypertrophic cardiomyopathy. Int J Cardiol. 2025 May 01; 426:133082.
    View in: PubMed
    Score: 0.061
  191. Sharkey SW, Lesser JR, Zenovich AG, Maron MS, Lindberg J, Longe TF, Maron BJ. Acute and reversible cardiomyopathy provoked by stress in women from the United States. Circulation. 2005 Feb 01; 111(4):472-9.
    View in: PubMed
    Score: 0.061
  192. Massera D, Sherrid MV, Adlestein E, Bokhari N, Alvarez IC, Wu WY, Reuter MC, Maron MS, Maron BJ, Rowin EJ. Disopyramide Revisited for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Efficacy and Safety in Patients Treated for at Least 5?Years. J Am Heart Assoc. 2025 Jan 21; 14(2):e037639.
    View in: PubMed
    Score: 0.061
  193. Maron BJ, Dearani JA, Ommen SR, Maron MS, Schaff HV, Gersh BJ, Nishimura RA. The case for surgery in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004 Nov 16; 44(10):2044-53.
    View in: PubMed
    Score: 0.060
  194. Aglan A, Fath AR, Maron BJ, Maron MS, Prasad A, Almomani A, Hammadah M, Reynolds MR, Rowin EJ. Percutaneous left atrial appendage closure for stroke prevention in hypertrophic cardiomyopathy patients with atrial fibrillation. Heart Rhythm. 2024 09; 21(9):1677-1683.
    View in: PubMed
    Score: 0.058
  195. Maron BA, Wang RS, Shevtsov S, Drakos SG, Arons E, Wever-Pinzon O, Huggins GS, Samokhin AO, Oldham WM, Aguib Y, Yacoub MH, Rowin EJ, Maron BJ, Maron MS, Loscalzo J. Author Correction: Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes. Nat Commun. 2024 Apr 08; 15(1):3038.
    View in: PubMed
    Score: 0.058
  196. Narayanan CA, Bokhari N, Rowin EJ, Maron MS, Maron BJ, Link MS, Madias C. Maintenance of Subcutaneous Implantable Cardioverter Defibrillators in Hypertrophic Cardiomyopathy Patients With Iatrogenic Left Bundle-Branch Block After Septal Myectomy. J Am Heart Assoc. 2024 Apr 16; 13(8):e033728.
    View in: PubMed
    Score: 0.058
  197. Aglan A, Fath AR, Eldaly AS, Anderson AS, Phillips JS, Maron BJ, Maron MS, Rowin EJ. Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Mortality in Hypertrophic Cardiomyopathy. JACC Adv. 2024 Mar; 3(3):100843.
    View in: PubMed
    Score: 0.057
  198. Carrick RT, Ahamed H, Sung E, Maron MS, Madias C, Avula V, Studley R, Bao C, Bokhari N, Quintana E, Rajesh-Kannan R, Maron BJ, Wu KC, Rowin EJ. Identification of high-risk imaging features in hypertrophic cardiomyopathy using electrocardiography: A deep-learning approach. Heart Rhythm. 2024 08; 21(8):1390-1397.
    View in: PubMed
    Score: 0.057
  199. Studley R, Madias C, Bokhari N, Carrick RT, Quintana E, Bao C, Maron BJ, Maron MS, Rowin EJ. QRS Fragmentation as a Risk Marker for Sudden Death in Hypertrophic Cardiomyopathy. JACC Clin Electrophysiol. 2023 11; 9(11):2353-2355.
    View in: PubMed
    Score: 0.055
  200. Bataiosu R, Hoss S, Scolari FL, Cooper C, Tsoi M, Brahmbhatt DH, Billia F, Lee DZJ, Chan R, Ha ACT, Maron BJ, Rowin E, Maron MS, Ralph-Edwards A, Rakowski H, Adler A. Clinical Significance of Postoperative Atrial Fibrillation in Hypertrophic Cardiomyopathy Patients Undergoing Septal Myectomy. Can J Cardiol. 2023 12; 39(12):1931-1937.
    View in: PubMed
    Score: 0.055
  201. Maron BJ, Estes NA, Maron MS, Almquist AK, Link MS, Udelson JE. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation. 2003 Jun 17; 107(23):2872-5.
    View in: PubMed
    Score: 0.055
  202. Wang RS, Rowin EJ, Maron BJ, Maron MS, Maron BA. A novel patient-patient network medicine approach to refine hypertrophic cardiomyopathy subgrouping: implications for risk stratification. Cardiovasc Res. 2023 05 02; 119(3):e125-e127.
    View in: PubMed
    Score: 0.054
  203. Maron BA, Wang RS, Shevtsov S, Drakos SG, Arons E, Wever-Pinzon O, Huggins GS, Samokhin AO, Oldham WM, Aguib Y, Yacoub MH, Rowin EJ, Maron BJ, Maron MS, Loscalzo J. Author Correction: Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes. Nat Commun. 2022 Nov 17; 13(1):7026.
    View in: PubMed
    Score: 0.052
  204. Larson A, Codden CJ, Huggins GS, Rastegar H, Chen FY, Maron BJ, Rowin EJ, Maron MS, Chin MT. Altered intercellular communication and extracellular matrix signaling as a potential disease mechanism in human hypertrophic cardiomyopathy. Sci Rep. 2022 03 25; 12(1):5211.
    View in: PubMed
    Score: 0.050
  205. Sridharan A, Maron MS, Carrick RT, Madias CA, Huang D, Cooper C, Drummond J, Maron BJ, Rowin EJ. Impact of comorbidities on atrial fibrillation and sudden cardiac death in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2022 01; 33(1):20-29.
    View in: PubMed
    Score: 0.049
  206. Sherrid MV, Swistel DG, Olivotto I, Pieroni M, Wever-Pinzon O, Riedy K, Bach RG, Husaini M, Cresci S, Reyentovich A, Massera D, Maron MS, Maron BJ, Kim B. Syndrome of Reversible Cardiogenic Shock and Left Ventricular Ballooning in Obstructive Hypertrophic Cardiomyopathy. J Am Heart Assoc. 2021 10 19; 10(20):e021141.
    View in: PubMed
    Score: 0.049
  207. Carrick RT, Maron MS, Adler A, Wessler B, Hoss S, Chan RH, Sridharan A, Huang D, Cooper C, Drummond J, Rakowski H, Maron BJ, Rowin EJ. Development and Validation of a Clinical Predictive Model for Identifying Hypertrophic Cardiomyopathy Patients at Risk for Atrial Fibrillation: The HCM-AF Score. Circ Arrhythm Electrophysiol. 2021 06; 14(6):e009796.
    View in: PubMed
    Score: 0.047
  208. Papanastasiou CA, Zegkos T, Karamitsos TD, Rowin EJ, Maron MS, Parcharidou D, Kokkinidis DG, Karvounis H, Rimoldi O, Maron BJ, Efthimiadis GK. Prognostic role of left ventricular apical aneurysm in hypertrophic cardiomyopathy: A systematic review and meta-analysis. Int J Cardiol. 2021 06 01; 332:127-132.
    View in: PubMed
    Score: 0.047
  209. Maron BA, Wang RS, Shevtsov S, Drakos SG, Arons E, Wever-Pinzon O, Huggins GS, Samokhin AO, Oldham WM, Aguib Y, Yacoub MH, Rowin EJ, Maron BJ, Maron MS, Loscalzo J. Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes. Nat Commun. 2021 02 08; 12(1):873.
    View in: PubMed
    Score: 0.046
  210. Habib M, Adler A, Fardfini K, Hoss S, Hanneman K, Rowin EJ, Maron MS, Maron BJ, Rakowski H, Chan RH. Progression of Myocardial Fibrosis in Hypertrophic Cardiomyopathy: A Cardiac Magnetic Resonance Study. JACC Cardiovasc Imaging. 2021 05; 14(5):947-958.
    View in: PubMed
    Score: 0.046
  211. Kumar KR, Mandleywala SN, Madias C, Weinstock J, Rowin EJ, Maron BJ, Maron MS, Link MS. Single Coil Implantable Cardioverter Defibrillator Leads in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2020 06 15; 125(12):1896-1900.
    View in: PubMed
    Score: 0.044
  212. Sherrid MV, Riedy K, Rosenzweig B, Massera D, Saric M, Swistel DG, Ahluwalia M, Arabadjian M, DeFonte M, Stepanovic A, Serrato S, Xia Y, Zhong H, Maron MS, Maron BJ, Reynolds HR. Distinctive Hypertrophic Cardiomyopathy Anatomy and Obstructive Physiology in Patients Admitted With Takotsubo Syndrome. Am J Cardiol. 2020 06 01; 125(11):1700-1709.
    View in: PubMed
    Score: 0.043
  213. Kimmelstiel C, Zisa DC, Kuttab JS, Wells S, Udelson JE, Wessler BS, Rastegar H, Kapur NK, Weintraub AR, Maron BJ, Maron MS, Rowin EJ. Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical Outcomes. Circ Cardiovasc Interv. 2019 07; 12(7):e007673.
    View in: PubMed
    Score: 0.042
  214. Thiene G, Rizzo S, Schiavon M, Maron MS, Zorzi A, Corrado D, Maron BJ, Basso C. Structurally Normal Hearts Are Uncommonly Associated With Sudden Deaths in Athletes and Young People. J Am Coll Cardiol. 2019 06 18; 73(23):3031-3032.
    View in: PubMed
    Score: 0.041
  215. Miller CAS, Maron MS, Estes NAM, Price LL, Rowin EJ, Maron BJ, Link MS. Safety, Side Effects and Relative Efficacy of Medications for Rhythm Control of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Am J Cardiol. 2019 06 01; 123(11):1859-1862.
    View in: PubMed
    Score: 0.041
  216. Solomon Z, Breton C, Rowin EJ, Maron BJ, Maron MS, Chen FY, Rastegar H. Surgical Approaches to Hypertrophic Obstructive Cardiomyopathy. Semin Thorac Cardiovasc Surg. 2018; 30(2):125-128.
    View in: PubMed
    Score: 0.038
  217. Rowin EJ, Maron BJ, Abt P, Kiernan MS, Vest A, Costantino F, Maron MS, DeNofrio D. Impact of Advanced Therapies for Improving Survival to Heart Transplant in Patients with Hypertrophic Cardiomyopathy. Am J Cardiol. 2018 04 15; 121(8):986-996.
    View in: PubMed
    Score: 0.038
  218. Kannappan M, Maron BJ, Rastegar H, Pandian NG, Maron MS, Rowin EJ. Underappreciated occurrence of discrete subaortic membranes producing left ventricular outflow obstruction in hypertrophic cardiomyopathy. Echocardiography. 2017 Aug; 34(8):1247-1249.
    View in: PubMed
    Score: 0.036
  219. Rastegar H, Boll G, Rowin EJ, Dolan N, Carroll C, Udelson JE, Wang W, Carpino P, Maron BJ, Maron MS, Chen FY. Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience. Ann Cardiothorac Surg. 2017 Jul; 6(4):353-363.
    View in: PubMed
    Score: 0.036
  220. Covella M, Rowin EJ, Hill NS, Preston IR, Milan A, Opotowsky AR, Maron BJ, Maron MS, Maron BA. Mechanism of Progressive Heart Failure and Significance of Pulmonary Hypertension in Obstructive Hypertrophic Cardiomyopathy. Circ Heart Fail. 2017 Apr; 10(4):e003689.
    View in: PubMed
    Score: 0.035
  221. Wang W, Lian Z, Rowin EJ, Maron BJ, Maron MS, Link MS. Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy. Circ Arrhythm Electrophysiol. 2017 Mar; 10(3).
    View in: PubMed
    Score: 0.035
  222. Weissler-Snir A, Hindieh W, Gruner C, Fourey D, Appelbaum E, Rowin E, Care M, Lesser JR, Haas TS, Udelson JE, Manning WJ, Olivotto I, Tomberli B, Maron BJ, Maron MS, Crean AM, Rakowski H, Chan RH. Lack of Phenotypic Differences by Cardiovascular Magnetic Resonance Imaging in MYH7 (?-Myosin Heavy Chain)- Versus MYBPC3 (Myosin-Binding Protein C)-Related Hypertrophic Cardiomyopathy. Circ Cardiovasc Imaging. 2017 Feb; 10(2).
    View in: PubMed
    Score: 0.035
  223. Williams LK, Chan RH, Carasso S, Durand M, Misurka J, Crean AM, Ralph-Edwards A, Gruner C, Woo A, Lesser JR, Maron BJ, Maron MS, Rakowski H. Effect of Left Ventricular Outflow Tract Obstruction on Left Atrial Mechanics in Hypertrophic Cardiomyopathy. Biomed Res Int. 2015; 2015:481245.
    View in: PubMed
    Score: 0.032
  224. Caselli S, Maron MS, Urbano-Moral JA, Pandian NG, Maron BJ, Pelliccia A. Differentiating left ventricular hypertrophy in athletes from that in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2014 Nov 01; 114(9):1383-9.
    View in: PubMed
    Score: 0.030
  225. Biagini E, Olivotto I, Iascone M, Parodi MI, Girolami F, Frisso G, Autore C, Limongelli G, Cecconi M, Maron BJ, Maron MS, Rosmini S, Formisano F, Musumeci B, Cecchi F, Iacovoni A, Haas TS, Bacchi Reggiani ML, Ferrazzi P, Salvatore F, Spirito P, Rapezzi C. Significance of sarcomere gene mutations analysis in the end-stage phase of hypertrophic cardiomyopathy. Am J Cardiol. 2014 Sep 01; 114(5):769-76.
    View in: PubMed
    Score: 0.029
  226. Harrigan CJ, Peters DC, Gibson CM, Maron BJ, Manning WJ, Maron MS, Appelbaum E. Hypertrophic cardiomyopathy: quantification of late gadolinium enhancement with contrast-enhanced cardiovascular MR imaging. Radiology. 2011 Jan; 258(1):128-33.
    View in: PubMed
    Score: 0.023
  227. Sharkey SW, Maron BJ, Nelson P, Parpart M, Maron MS, Bristow MR. Adrenergic receptor polymorphisms in patients with stress (tako-tsubo) cardiomyopathy. J Cardiol. 2009 Feb; 53(1):53-7.
    View in: PubMed
    Score: 0.020
  228. Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, Gersh BJ, Ackerman MJ, McCully RB, Dearani JA, Schaff HV, Danielson GK, Tajik AJ, Nishimura RA. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005 Aug 02; 46(3):470-6.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.